Hypothetical Scenario
|
|
- Paulina Dean
- 6 years ago
- Views:
Transcription
1 Using Indirect and Multiple Treatment Comparisons Methods To Estimate Comparative Effectiveness of Alternative Treatments Workshop September 27, 2010 Beth Devine, PharmD, MBA, PhD Rafael Alfonso C., MD, MSc UW Pharmaceutical Outcomes Research & Policy Program Hypothetical Scenario Your institution is deciding on treatments for Rheumatoid Arthritis and YOU have been selected to review the comparative effectiveness of biologic therapies in patients who have inadequate response to oral DMARDs, especially Methotrexate. Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. Evidence Based Medicine Framework Question PICO Literature search Validity/Strength of Infer rence Time Spent in Critical Appraisa al Appraisal Levels of evidence Integrate evidence 1
2 Literature Search We performed a literature search to identify the best available evidence of biological therapies for RA in patients with MTX IR Only RCT comparing biologic therapies to placebo or MTX, no head to head comparison across all the available treatments Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. Network of studies available Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. Meta analysis Quantitatively combined results of comparable studies of the same agent to obtain overall estimate of effect. Indirect Treatment Comparison Statistical comparison of two or more agents that have not been directly compared to each other, but that have one comparator in common, thus creating a network Mixed Treatment Comparison Extension of ITC where both direct and indirect evidence is included Validity of evidence synthesis relies on methods that: appreciate within trial randomization and Limit bias due to lack of randomization across trials Jansen. Value in Health 2008;11(5):956-64; Lumley. Stat Med 2002;21: ; Lu & Ades. Stat Med 2004;23: ; Sutton & Ades. Pharmacoeconomics 2008;26(9);
3 ITC/MTC Assumptions Song. BMJ 2009;338:b1174 Statistical Methods Fixed effects models We believe all trials estimate the same treatment effect Mantel Haenszel method Peto method Random effects models We believe there is variability between studies; that there is a true mean effect and the effect from each study is distributed around that mean DerSimonian Laird method Statistical Methods Frequentist Probability is the limit of relative frequency (Pr(A B) Assumes experiment can be repeated under identical conditions Only applies to events that have not yet occurred Once data collected, probability no longer applies! After data collected can only describe uncertainty Applies to repetitititititive phenomena Flipping a coin Hollenbeak.ISPOR. May 15, 2010 Thompson. The Stata Journal 2006;6(4): Bayesian Based on subjective probability Probability is my degree of belief in a statement Probability y describes uncertainty Uncertainty has a probability distribution Obtain a distribution of your model parameters Parameters are random and data are fixed Calculate 95% credible intervals Probability the event lies within the interval P(B A) = [P(A B)p(B)] / P(A) 3
4 Statistical Methods Monte Carlo simulation estimates random sequence of chains, where next chain relies only on its immediate predecessor Markov chain Markov chain Monte Carlo simulation (MCMC) set up a Markov chain whose distribution is the posterior distribution Chain must run to convergence before estimating posterior probabilities burn ins A special type of algorithm cycles through each model parameter one at a time is called Gibbs sampling WinBUGS = Bayesian inference Using Gibbs Sampling, for Windows or Lunn, Thomas, Best, Speigelhalter. Stat Comput 2000;10: Thompson. The Stata Journal 2006;6(4): Methods: Model Development Two random effects logistic regression models (6 and 12 months), using the ACR 50 as the primary outcome. Randomization was preserved MTX and/or placebo, as common comparators to biologics. Mean disease duration and Mean baseline HAQ DI score were included as meta regression covariates, to account for heterogeneity between trials These covariates have prognostic value in determining the effect of RA treatment Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. Methods: Model Compilation and Running the Models Our statistical model is represented by the following equations: For the control arms: logit (p i 0) = α i + β i m i 0 For the treatment arms: logit (pij) = αi + βimij + θi + γ1x1i + γ2x2i and j=1, Ji We ran three chains and 20,000 iterations after a burn in of 10,000 iterations. We assessed the accuracy of the posterior assessments by calculating the Monte Carlo error for each parameter. For nomenclature see notes below Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. 4
5 Results: 6 months In the 6 month model, when compared to placebo, all biologic DMARDS and MTX were significantly more efficacious and ranked in the following order: Certolizumab (median log odds ratio=2.6), tocilizumab (1.7), rituximab (1.6), infliximab (1.6), etanercept (1.4), adulimumab (1.4), golimumab (1.4), abatacept (1.2), anakinra (1.0), MTX (0.8). There were 45 pairwise comparisons. Certolizumab was significantly more efficacious than MTX; none others were significant. Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. 6-month Model - Pairwise comparisons between biologic DMARDS and MTX (99.9% CrI) 6 month model - Odds ratios by treatment and disease duration compared to comparator (95% CrI) 5
6 Results: 12 months The rank order in the 12 month analysis was: Certolizumab (2.0), rituximab (2.0), adalimumab (1.4), infliximab (1.4), etanercept (0.9), abatacept (0.6), and MTX (0.8). There were 21 pairwisecomparisons; nonewere significant. The results of the model parameterized by therapeutic class revealed that each class was more efficacious than placebo. In pairwise comparisons, each class was more efficacious than MTX, but none more efficacious than another. Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. Limitations We assumed treatment effects are exchangeable between studies for both biologic and MTX treatment We assumed treatment effect similar between study arms withineachstudy didnotdifferentiate differentiate amongdoses We evaluated only one outcome ACR50(not safety) Meta regression controlled for some, but not all, between study heterogeneity Our results are dependent on the studies included We did not address publication bias Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. Conclusions Using emerging ITC methods enabled us to compare the efficacy of biologic DMARDS for treatment of RA in the absence of head to head trials. Our methods enabled us to rank order these treatments. Further analysis by drug and by therapeutic class suggests that biologic DMARDS are similarly efficacious. Based on the manuscript to be published in Pharmacotherpy by: Devine BE, Alfonso Cristancho R, Sullivan S. 6
7 Now Let s Practice using WinBUGS! Advantage of Bayesian analysis in ITC/ MTC is that it allows calculation of the probability of which treatment is best or Lunn, Thomas, Best, Speigelhalter. Stat Comput 2000;10: Outcome Measures How is your outcome of interest measured? Binary (e.g. dead or alive) Continuous (e.g blood pressure) Categorical/ordinal (e.g. severity scale) Bi Binary outcomes most common We will consider here Continuous Similar approach to binary Ordinal More complex and more rare 7
8 Binary Outcome Measures Binary outcome data from a comparative study can be expressed in a 2 x 2 table RCT Failure/Dead New Treatment A B Control C d Success/Alive Three common outcome measures: Odds ratios, risk ratios, risk differences Binary Outcome Measures Odds ratios OR = ad/bc Var ln(or) = 1/a + 1/b + 1/c + 1/d Work on log (ln) scale due to better statistical properties Relative Risk RR (a/(a+b))/ (c/(c+d)) Var ln(or) = 1/a 1/(a+b) + 1/c 1/(c+d) Work on log (ln) scale due to better statistical properties Binary Outcome Measures Risk Difference RD = (a/(a+b)) (c/(c+d)) Var = [p 1 / (1 p 1 ]/n 1 + [p 2 / (1 p 2 ]/n 2 ] Where: p 1 = a/(a+b) p 2 = c/(c+d) n 1 = a+b and n 2 = c+d 8
9 Fixed Effects Model Statistical homogeneity Formally assume: Y i = Normal(d,V i ) Random error We estimate the common true effect, d Point estimate True effect Generic Fixed Effect Y i ~ Normal(d,V i ) where i= 1.N studies Y i is the observed effect in study i with Variance V i All studies assumed to be measuring the same underlying effect size, d For a Bayesian analysis, a prior distribution must be specified for d Choice of Prior for d Often, amount of information in studies is large enough to render any prior of little importance therefore choice not critical Often specified as vague or flat Often specified as vague or flat E.g. If meta analysis is on ln(or) scale, could specify d~normal (0, 10 5 ) This states a priori we would be 95% certain that true value of d is between [0±1.96( 10 5 )] On OR scale: to very flat! 9
10 Fixed Effect with Prior Y i ~ Normal(d,V i ) where i= 1.N studies d ~ Normal(0, 10 5 ) Models are specified in WinBUGS using formulas similar to this algebra Note: Normal distributions are specified by mean and precision where precision = 1/variance Estimate model paramter using MCMC, rather than inverse weighting of variance Example: Meta analysis, RCTs of effect of aspirin preventing death after acute MIs Study Aspirin Group Placebo Group Deaths Total Deaths Total MRC CDP MRC GASP PARIS AMIS ISIS Fleiss 1993 Example: Calculation: Log(OR) & Variance For MCR 1 Survive Die Aspirin Placebo OR=(566*67)/ 67)/ (557*49) = Log(ln)OR = Variance lnor = 1/ /49 + 1/ /67 = Note this is OR for Survival If 2x2 table contains any zeros, common to add 0.5 to those cells before calculations 10
11 Example:Aspirin Data to be Combined Study OR LnOR (Y i ) Var(lnOR) (V i ) Weight (1/V i ) MRC CDP MRC GASP PARIS AMIS ISIS Note: ISIS-2 with small variance and large weight (1/0.002) Launch WinBUGS Click on WinBUGS14.exe Click File Open Load aspirin FE.odc Components of WinBUGS.odc file Model { < Likelihood> <Prior distributions> } #Data <List or column format> #Starting Values <List or mixture of list and column format> 11
12 Steps for Running a Model in WinBUGS 1. Make model active. Doodles: If in own window, click title bar. If in compound document, double click the doodle (should have hairy border). Text: Simply highlight the word model at the beginning of your model. 2. Bring up Model Specification Tool (menu: Model > Specification) 3. Click check model Should see model is syntactically correct in lower left corner of window. 4. Highlight first row of data containing variable labels (if in rectangular format) 5. Click load data Should see data is loaded in lower left corner of window. 6. If using multiple chains, enter number in num of chains box. Otherwise, proceed. 7. Click compile Should see model is compiled in lower left corner of window. 8. Highlight line containing initial values: list( ) 9. Click load inits If using multiple chains, you will need to repeat steps 8 9 for each chain. Should see model is initialized. 10. Bring up Sample Monitor Tool (menu: Inference > Samples) Enter name of each node you wish to monitor and click set 11. Bring up Update Tool (menu: Model > Update) 12. Enter a number of samples to take and click update. Should see model is updating. Load and Check Model 12
13 Load and Check Data Compile Compile Model Model Load Initials 13
14 Pooled OR: median 1.12 (1.05 to 1.19) 14
15 Random Effects Model Model Within studies Y i ~Normal( i,vi) Across studies ~Normal(d 2 I Normal(d, ) d=solid line =dotted lines 2 = variability between studies (heterogeneity) Y 5 Trial-specific effects=dotted lines True Mean Effect = solid line 5 Generic Random Effect Y i ~ Normal(,V i ) where i= 1.N studies i ~ Normal(d, 2 ) As for fixed effect, Y i is observed effect in study i with variance V i Now study specific effects, I are allowed to be different from each other and are assumed to be sampled from a Normal distribution with mean d and variance 2 For a Bayesian analysis, a prior distribution is required for 2 as well as for d Choice of Prior for 2 This is a little trickier than for d Variances cannot be negative so Normal distribution is not a good choice Examples in WinBUGS Manual use Uniform distribution. E.g. ~ Uniform (0,10) of 10 is massive, because we are working with ORs; even of 1 or 2 is large Specification of vague priors on variance components is complex and is an active area of research 15
16 Generic Random Effects Model Load aspirin RE.odc 16
17 Results of Aspirin RE model Pooled OR: median ( ) OR now contains 1 Heterogeneity (log scale)=0.02 (95% CrI: 0 0.4) Compare with FE model: Pooled OR: median 1.12 (1.05 to 1.19) Bayesian CrI wider than classical CI 2 is random variable and uncertainty is included in pooled result Random Effects Binomial Model Load aspirin RE bin.odc If ORs are being pooled it is possible to specify a model that does not require assumption of normality of study effect sizes Useful when events are rare Avoids need to add continuity correction factors when cells with 0 events exist Considered more exact Based on logistic regression Random Effects Binomial Model r Ai ~Bin(p Ai, n Ai ) r Bi ~Bin(p Bi, n Bi ) logit(p Ai )=µ i logit(p Bi )=µ i + i i ~N(d, 2 ) where i=1...n studies n and n = total number of patientsin ith study n Ai and n Bi = total number of patients in ith study r Ai and r Bi = total number of events in each group p Ai and p Bi = underlying probabilities of event in each group µ i = estimated log odds of event in group A (requires prior) I = log (OR) between groups d=true mean effect; =heterogeneity between studies Logit(p)=log((p)/(1 p)) unconstrained scale used logistic regression 17
18 Compare our Three Odds Ratios and CrIs Fixed effects Normal Distribution OR=1.12 (95% CrI: 1.05, 1.19) Random Effects Normal Distribution OR=1.15 (95% CrI: 0.97, 1.44) Random Effects Binary Distribution OR=1.14 (95% CrI: 0.98, 1.44) MCMC Basics Now that we ve run a few models consider sensitivity analyses Sensitivity to prior distributions esp. important for distributions of variance/precision parameters Sensitivityto initialvalues Sensitivity to initial values Multiple chains using very different starting values & comparing using Brooks Gelman Rubin Statistics Length of burn in & ample: examine history/trace plots Auto correlation high auto correlation suggests samples are not independent & poor/slow mixing of chains: Run model longer or reparameterize (center variables) Convergence diagnostics & CODA & BOA 18
19 Interpreting Random Effects A single parameter cannot adequately summarize heterogeneous effects Therefore estimation and reporting of 2 is important This tells us how much variability there is between estimates from the population of studies In some instances studies contain both beneficial and harmful effects very important! Looking to the Future (The Future is Here!) Data Sources Evidence Synthesis RCT1 RCT2 Obs 1 Routine Care Meta- Analysis General Synthesis Bayes Theorem Combination Model Clinical Adverse Inputs (w/ Effects Effects undertainty) Decision Model Tx A Fib Warfarin NO Warfarin Stroke No Strk Stroke No Strk Bleed NoBld Bleed NoBld Bleed NoBld Bleed NoBld Utility Utility Utility Utility Utility Utility Utility Utility Cost Cost Cost Cost Cost Cost Cost Costs Questions? 19
5/10/2010. ISPOR Good Research Practices for Comparative Effectiveness Research: Indirect Treatment Comparisons Task Force
ISPOR Good Research Practices for Comparative Effectiveness Research: Indirect Treatment Comparisons Task Force Presentation of Two Draft Reports 17 May 2010 ITC Task Force: Leadership Team Lieven Annemans
More informationAn Empirical Assessment of Bivariate Methods for Meta-analysis of Test Accuracy
Number XX An Empirical Assessment of Bivariate Methods for Meta-analysis of Test Accuracy Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 54 Gaither
More informationDiscussion Leaders. Workshop Outline. David J. Vanness, PhD. Ágnes Benedict, MA, MS. Background
Discussion Leaders David J. Vanness, PhD Assistant Professor, Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health Ágnes Benedict, MA, MS GENERALIZED EVIDENCE
More informationModelling heterogeneity variances in multiple treatment comparison meta-analysis Are informative priors the better solution?
Thorlund et al. BMC Medical Research Methodology 2013, 13:2 RESEARCH ARTICLE Open Access Modelling heterogeneity variances in multiple treatment comparison meta-analysis Are informative priors the better
More informationThe use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis
Schmitz et al. BMC Medical Research Methodology 2012, 12:167 RESEARCH ARTICLE Open Access The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis Susanne Schmitz
More informationMethods Research Report. An Empirical Assessment of Bivariate Methods for Meta-Analysis of Test Accuracy
Methods Research Report An Empirical Assessment of Bivariate Methods for Meta-Analysis of Test Accuracy Methods Research Report An Empirical Assessment of Bivariate Methods for Meta-Analysis of Test Accuracy
More informationComparison of Meta-Analytic Results of Indirect, Direct, and Combined Comparisons of Drugs for Chronic Insomnia in Adults: A Case Study
ORIGINAL ARTICLE Comparison of Meta-Analytic Results of Indirect, Direct, and Combined Comparisons of Drugs for Chronic Insomnia in Adults: A Case Study Ben W. Vandermeer, BSc, MSc, Nina Buscemi, PhD,
More informationWinBUGS : part 1. Bruno Boulanger Jonathan Jaeger Astrid Jullion Philippe Lambert. Gabriele, living with rheumatoid arthritis
WinBUGS : part 1 Bruno Boulanger Jonathan Jaeger Astrid Jullion Philippe Lambert Gabriele, living with rheumatoid arthritis Agenda 2 Introduction to WinBUGS Exercice 1 : Normal with unknown mean and variance
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationBayesian Inference Bayes Laplace
Bayesian Inference Bayes Laplace Course objective The aim of this course is to introduce the modern approach to Bayesian statistics, emphasizing the computational aspects and the differences between the
More informationBAYESIAN HYPOTHESIS TESTING WITH SPSS AMOS
Sara Garofalo Department of Psychiatry, University of Cambridge BAYESIAN HYPOTHESIS TESTING WITH SPSS AMOS Overview Bayesian VS classical (NHST or Frequentist) statistical approaches Theoretical issues
More informationOrdinal Data Modeling
Valen E. Johnson James H. Albert Ordinal Data Modeling With 73 illustrations I ". Springer Contents Preface v 1 Review of Classical and Bayesian Inference 1 1.1 Learning about a binomial proportion 1 1.1.1
More informationAn Introduction to Using WinBUGS for Cost-Effectiveness Analyses in Health Economics
Meta-Analyses and Mixed Treatment Comparisons Slide 1 An Introduction to Using WinBUGS for Cost-Effectiveness Analyses in Health Economics Dr. Christian Asseburg Centre for Health Economics Part 2 Meta-Analyses
More informationFundamental Clinical Trial Design
Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003
More informationModels for potentially biased evidence in meta-analysis using empirically based priors
Models for potentially biased evidence in meta-analysis using empirically based priors Nicky Welton Thanks to: Tony Ades, John Carlin, Doug Altman, Jonathan Sterne, Ross Harris RSS Avon Local Group Meeting,
More informationSystematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy
Systematic review with multiple treatment comparison metaanalysis on interventions for hepatic encephalopathy Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with severe
More informationMediation Analysis With Principal Stratification
University of Pennsylvania ScholarlyCommons Statistics Papers Wharton Faculty Research 3-30-009 Mediation Analysis With Principal Stratification Robert Gallop Dylan S. Small University of Pennsylvania
More informationBayesian Statistics Estimation of a Single Mean and Variance MCMC Diagnostics and Missing Data
Bayesian Statistics Estimation of a Single Mean and Variance MCMC Diagnostics and Missing Data Michael Anderson, PhD Hélène Carabin, DVM, PhD Department of Biostatistics and Epidemiology The University
More informationHierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes
Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes Fiona C. Warren a*, Keith R. Abrams b, Alex J. Sutton b a
More informationGUIDELINE COMPARATORS & COMPARISONS:
GUIDELINE COMPARATORS & COMPARISONS: Direct and indirect comparisons Adapted version (2015) based on COMPARATORS & COMPARISONS: Direct and indirect comparisons - February 2013 The primary objective of
More informationIntroduction to Bayesian Analysis 1
Biostats VHM 801/802 Courses Fall 2005, Atlantic Veterinary College, PEI Henrik Stryhn Introduction to Bayesian Analysis 1 Little known outside the statistical science, there exist two different approaches
More informationHierarchical Bayesian Modeling of Individual Differences in Texture Discrimination
Hierarchical Bayesian Modeling of Individual Differences in Texture Discrimination Timothy N. Rubin (trubin@uci.edu) Michael D. Lee (mdlee@uci.edu) Charles F. Chubb (cchubb@uci.edu) Department of Cognitive
More informationEffective Health Care Program
Comparative Effectiveness Review Number 55 Effective Health Care Program Drug Therapy for Rheumatoid Arthritis in Adults: An Update Executive Summary Background Rheumatoid arthritis (RA), which affects
More informationBayesian Logistic Regression Modelling via Markov Chain Monte Carlo Algorithm
Journal of Social and Development Sciences Vol. 4, No. 4, pp. 93-97, Apr 203 (ISSN 222-52) Bayesian Logistic Regression Modelling via Markov Chain Monte Carlo Algorithm Henry De-Graft Acquah University
More informationA Brief Introduction to Bayesian Statistics
A Brief Introduction to Statistics David Kaplan Department of Educational Psychology Methods for Social Policy Research and, Washington, DC 2017 1 / 37 The Reverend Thomas Bayes, 1701 1761 2 / 37 Pierre-Simon
More informationBayesian Mediation Analysis
Psychological Methods 2009, Vol. 14, No. 4, 301 322 2009 American Psychological Association 1082-989X/09/$12.00 DOI: 10.1037/a0016972 Bayesian Mediation Analysis Ying Yuan The University of Texas M. D.
More informationAdvanced Bayesian Models for the Social Sciences. TA: Elizabeth Menninga (University of North Carolina, Chapel Hill)
Advanced Bayesian Models for the Social Sciences Instructors: Week 1&2: Skyler J. Cranmer Department of Political Science University of North Carolina, Chapel Hill skyler@unc.edu Week 3&4: Daniel Stegmueller
More informationA Case Study: Two-sample categorical data
A Case Study: Two-sample categorical data Patrick Breheny January 31 Patrick Breheny BST 701: Bayesian Modeling in Biostatistics 1/43 Introduction Model specification Continuous vs. mixture priors Choice
More informationBayesian Methods p.3/29. data and output management- by David Spiegalhalter. WinBUGS - result from MRC funded project with David
Bayesian Methods - I Dr. David Lucy d.lucy@lancaster.ac.uk Lancaster University Bayesian Methods p.1/29 The package we shall be looking at is. The Bugs bit stands for Bayesian Inference Using Gibbs Sampling.
More informationBayesian and Frequentist Approaches
Bayesian and Frequentist Approaches G. Jogesh Babu Penn State University http://sites.stat.psu.edu/ babu http://astrostatistics.psu.edu All models are wrong But some are useful George E. P. Box (son-in-law
More informationMeta-analysis of few small studies in small populations and rare diseases
Meta-analysis of few small studies in small populations and rare diseases Christian Röver 1, Beat Neuenschwander 2, Simon Wandel 2, Tim Friede 1 1 Department of Medical Statistics, University Medical Center
More informationEvidence synthesis with limited studies
Evidence synthesis with limited studies Incorporating genuine prior information about between-study heterogeneity PSI conference 2018 Dr. Shijie (Kate) Ren, Research Fellow, School of Health and Related
More informationCombining Risks from Several Tumors Using Markov Chain Monte Carlo
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Environmental Protection Agency Papers U.S. Environmental Protection Agency 2009 Combining Risks from Several Tumors
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationAnalysis of Rheumatoid Arthritis Data using Logistic Regression and Penalized Approach
University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School November 2015 Analysis of Rheumatoid Arthritis Data using Logistic Regression and Penalized Approach Wei Chen
More informationBayesian Estimation of a Meta-analysis model using Gibbs sampler
University of Wollongong Research Online Applied Statistics Education and Research Collaboration (ASEARC) - Conference Papers Faculty of Engineering and Information Sciences 2012 Bayesian Estimation of
More informationIndex. Springer International Publishing Switzerland 2017 T.J. Cleophas, A.H. Zwinderman, Modern Meta-Analysis, DOI /
Index A Adjusted Heterogeneity without Overdispersion, 63 Agenda-driven bias, 40 Agenda-Driven Meta-Analyses, 306 307 Alternative Methods for diagnostic meta-analyses, 133 Antihypertensive effect of potassium,
More informationApplications of Bayesian methods in health technology assessment
Working Group "Bayes Methods" Göttingen, 06.12.2018 Applications of Bayesian methods in health technology assessment Ralf Bender Institute for Quality and Efficiency in Health Care (IQWiG), Germany Outline
More informationComparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods
Comparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods John W Stevens Reader in Decision Science University of Sheffield EFPSI European Statistical Meeting
More informationMethod Comparison for Interrater Reliability of an Image Processing Technique in Epilepsy Subjects
22nd International Congress on Modelling and Simulation, Hobart, Tasmania, Australia, 3 to 8 December 2017 mssanz.org.au/modsim2017 Method Comparison for Interrater Reliability of an Image Processing Technique
More informationNetwork Meta-Analysis for Comparative Effectiveness Research
Network Meta-Analysis for Comparative Effectiveness Research Joseph C. Cappelleri, Ph.D., M.P.H. Pfizer Inc Groton, CT e-mail:joseph.c.cappelleri@pfizer.com Oral presentation at the 19 th Annual Biopharmaceutical
More informationWhat is indirect comparison?
...? series New title Statistics Supported by sanofi-aventis What is indirect comparison? Fujian Song BMed MMed PhD Reader in Research Synthesis, Faculty of Health, University of East Anglia Indirect comparison
More informationIndirect Comparisons: heroism or heresy. Neil Hawkins With acknowledgements to Sarah DeWilde
Indirect Comparisons: heroism or heresy Neil Hawkins With acknowledgements to Sarah DeWilde 1 Outline Brief introduction to indirect comparisons Two practical examples Heroism or Heresy? 2 A Taxonomy of
More informationChemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis
open access Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis Parambir S Dulai, 1 Siddharth Singh, 1,2 Evelyn Marquez,
More informationIndividual Differences in Attention During Category Learning
Individual Differences in Attention During Category Learning Michael D. Lee (mdlee@uci.edu) Department of Cognitive Sciences, 35 Social Sciences Plaza A University of California, Irvine, CA 92697-5 USA
More informationDraft Methods Report Number XX
Draft Methods Report Number XX Bayesian Approaches for Multiple Treatment Comparisons of Drugs for Urgency Urinary Incontinence are More Informative Than Traditional Frequentist Statistical Approaches
More informationAdvanced Bayesian Models for the Social Sciences
Advanced Bayesian Models for the Social Sciences Jeff Harden Department of Political Science, University of Colorado Boulder jeffrey.harden@colorado.edu Daniel Stegmueller Department of Government, University
More informationSystematic Reviews and meta-analyses of Diagnostic Test Accuracy. Mariska Leeflang
Systematic Reviews and meta-analyses of Diagnostic Test Accuracy Mariska Leeflang m.m.leeflang@amc.uva.nl This presentation 1. Introduction: accuracy? 2. QUADAS-2 exercise 3. Meta-analysis of diagnostic
More informationRheumatoid arthritis in adults: diagnosis and management
National Institute for Health and Care Excellence Final Rheumatoid arthritis in adults: diagnosis and management Rheumatoid arthritis: methods NICE guideline NG100 July 2018 Final Developed by the National
More informationMethods for meta-analysis of individual participant data from Mendelian randomization studies with binary outcomes
Methods for meta-analysis of individual participant data from Mendelian randomization studies with binary outcomes Stephen Burgess Simon G. Thompson CRP CHD Genetics Collaboration May 24, 2012 Abstract
More informationMeta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ
Tutorial in Biostatistics Received: 11 March 2016, Accepted: 13 September 2016 Published online 16 October 2016 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.7141 Meta-analysis using
More informationBayesian Meta-Analysis in Drug Safety Evaluation
Bayesian Meta-Analysis in Drug Safety Evaluation Amy Xia, PhD Amgen, Inc. BBS Meta-Analysis of Clinical Safety Data Seminar Oct 2, 2014 Disclaimer: The views expressed herein represent those of the presenter
More informationMultilevel IRT for group-level diagnosis. Chanho Park Daniel M. Bolt. University of Wisconsin-Madison
Group-Level Diagnosis 1 N.B. Please do not cite or distribute. Multilevel IRT for group-level diagnosis Chanho Park Daniel M. Bolt University of Wisconsin-Madison Paper presented at the annual meeting
More informationTNF-alpha inhibitors for ankylosing spondylitis(review)
Cochrane Database of Systematic Reviews Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MMS, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA MaxwellLJ,ZochlingJ,BoonenA,SinghJA,VerasMMS,TanjongGhogomuE,BenkhaltiJanduM,TugwellP,WellsGA.
More informationA COMPARISON OF BAYESIAN MCMC AND MARGINAL MAXIMUM LIKELIHOOD METHODS IN ESTIMATING THE ITEM PARAMETERS FOR THE 2PL IRT MODEL
International Journal of Innovative Management, Information & Production ISME Internationalc2010 ISSN 2185-5439 Volume 1, Number 1, December 2010 PP. 81-89 A COMPARISON OF BAYESIAN MCMC AND MARGINAL MAXIMUM
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationMeta-analysis of two studies in the presence of heterogeneity with applications in rare diseases
Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases Christian Röver 1, Tim Friede 1, Simon Wandel 2 and Beat Neuenschwander 2 1 Department of Medical Statistics,
More informationHow do we combine two treatment arm trials with multiple arms trials in IPD metaanalysis? An Illustration with College Drinking Interventions
1/29 How do we combine two treatment arm trials with multiple arms trials in IPD metaanalysis? An Illustration with College Drinking Interventions David Huh, PhD 1, Eun-Young Mun, PhD 2, & David C. Atkins,
More informationYou must answer question 1.
Research Methods and Statistics Specialty Area Exam October 28, 2015 Part I: Statistics Committee: Richard Williams (Chair), Elizabeth McClintock, Sarah Mustillo You must answer question 1. 1. Suppose
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466
Baricitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466 NICE 2017. All rights reserved. Subject to Notice of rights
More informationMS&E 226: Small Data
MS&E 226: Small Data Lecture 10: Introduction to inference (v2) Ramesh Johari ramesh.johari@stanford.edu 1 / 17 What is inference? 2 / 17 Where did our data come from? Recall our sample is: Y, the vector
More informationBayesian meta-analysis of Papanicolaou smear accuracy
Gynecologic Oncology 107 (2007) S133 S137 www.elsevier.com/locate/ygyno Bayesian meta-analysis of Papanicolaou smear accuracy Xiuyu Cong a, Dennis D. Cox b, Scott B. Cantor c, a Biometrics and Data Management,
More informationData Analysis Using Regression and Multilevel/Hierarchical Models
Data Analysis Using Regression and Multilevel/Hierarchical Models ANDREW GELMAN Columbia University JENNIFER HILL Columbia University CAMBRIDGE UNIVERSITY PRESS Contents List of examples V a 9 e xv " Preface
More informationUniversity of Bristol - Explore Bristol Research. Publisher's PDF, also known as Version of record
Dias, S., Welton, NJ., Sutton, AJ., Caldwell, DM., Lu, G., & Ades, AE. (2011). NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. (NICE
More informationTechnology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247
Tocilizumab for the treatment of rheumatoid arthritis Technology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationMeta-Analysis. Zifei Liu. Biological and Agricultural Engineering
Meta-Analysis Zifei Liu What is a meta-analysis; why perform a metaanalysis? How a meta-analysis work some basic concepts and principles Steps of Meta-analysis Cautions on meta-analysis 2 What is Meta-analysis
More informationDetection of Unknown Confounders. by Bayesian Confirmatory Factor Analysis
Advanced Studies in Medical Sciences, Vol. 1, 2013, no. 3, 143-156 HIKARI Ltd, www.m-hikari.com Detection of Unknown Confounders by Bayesian Confirmatory Factor Analysis Emil Kupek Department of Public
More informationMethods for assessing consistency in Mixed Treatment Comparison Meta-analysis
Methods for assessing consistency in Mixed Treatment Comparison Meta-analysis Sofia Dias, NJ Welton, AE Ades RSS 2009, Edinburgh Department of Community Based Medicine Overview Mixed Treatment Comparison
More informationKelvin Chan Feb 10, 2015
Underestimation of Variance of Predicted Mean Health Utilities Derived from Multi- Attribute Utility Instruments: The Use of Multiple Imputation as a Potential Solution. Kelvin Chan Feb 10, 2015 Outline
More informationBayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer
Original Manuscript Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer Medical Decision Making 1 15 Ó The Author(s) 2018
More informationA Comparison of Methods of Estimating Subscale Scores for Mixed-Format Tests
A Comparison of Methods of Estimating Subscale Scores for Mixed-Format Tests David Shin Pearson Educational Measurement May 007 rr0701 Using assessment and research to promote learning Pearson Educational
More informationAgenda. Frequent Scenario WS I: Treatment Comparisons and Network Meta-Analysis: Learning the Basics
WS I: onducting & Interpreting Indirect Treatment omparisons and Network Meta-nalysis: Learning the asics onducted by members of the ISPOR Indirect Treatment omparisons Task Force Joe appelleri PhD MPH
More informationLive WebEx meeting agenda
10:00am 10:30am Using OpenMeta[Analyst] to extract quantitative data from published literature Live WebEx meeting agenda August 25, 10:00am-12:00pm ET 10:30am 11:20am Lecture (this will be recorded) 11:20am
More informationSession 7: The Sliding Dichotomy 7.1 Background 7.2 Principles 7.3 Hypothetical example 7.4 Implementation 7.5 Example: CRASH Trial
Session 7: The Sliding Dichotomy 7.1 Background 7.2 Principles 7.3 Hypothetical example 7.4 Implementation 7.5 Example: CRASH Trial Session 7 1 7.1 The Sliding Dichotomy: Background The sliding dichotomy
More informationEmpirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study
Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study Jonathan Sterne, University of Bristol, UK Acknowledgements: Tony Ades, Bodil Als-Nielsen,
More informationComputational methods for evidence-based decision support
CIHC 2010 Computational methods for evidence-based decision support in pharmaceutical decision making Tommi Tervonen Econometric Institute, Erasmus University Rotterdam Eindhoven, 20/10/2010 Outline 1
More informationA COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY
A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,
More informationEmpirical assessment of univariate and bivariate meta-analyses for comparing the accuracy of diagnostic tests
Empirical assessment of univariate and bivariate meta-analyses for comparing the accuracy of diagnostic tests Yemisi Takwoingi, Richard Riley and Jon Deeks Outline Rationale Methods Findings Summary Motivating
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More informationMay 31, Re: Submission of revised manuscript (BMJ R1) Dear Drs. Villanueva and Godlee
May 31, 2016 Re: Submission of revised manuscript (BMJ.2016.032755.R1) Dear Drs. Villanueva and Godlee We greatly appreciate the positive critique of the reviewers' and the Editors in response to our revised
More informationRunning Head: BAYESIAN MEDIATION WITH MISSING DATA 1. A Bayesian Approach for Estimating Mediation Effects with Missing Data. Craig K.
Running Head: BAYESIAN MEDIATION WITH MISSING DATA 1 A Bayesian Approach for Estimating Mediation Effects with Missing Data Craig K. Enders Arizona State University Amanda J. Fairchild University of South
More informationHeavy menstrual bleeding (update)
National Institute for Health and Care Excellence Draft Heavy menstrual bleeding (update) NICE guideline: methods NICE guideline TBC Methods August 0 Draft for Consultation Evidence reviews were developed
More informationA Multilevel Testlet Model for Dual Local Dependence
Journal of Educational Measurement Spring 2012, Vol. 49, No. 1, pp. 82 100 A Multilevel Testlet Model for Dual Local Dependence Hong Jiao University of Maryland Akihito Kamata University of Oregon Shudong
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationMethods for evidence synthesis in the case of very few studies. Guido Skipka IQWiG, Cologne, Germany
Methods for evidence synthesis in the case of very few studies Guido Skipka IQWiG, Cologne, Germany 17 September 2018 Cochrane Colloquium 2018, Edinburgh, Statistical Methods Group meeting, G. Skipka 2
More informationAn Introduction to Bayesian Statistics
An Introduction to Bayesian Statistics Robert Weiss Department of Biostatistics UCLA Fielding School of Public Health robweiss@ucla.edu Sept 2015 Robert Weiss (UCLA) An Introduction to Bayesian Statistics
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationMETA-ANALYSIS FOR 2 x 2 TABLES: A BAYESIAN APPROACH
STATISTICS IN MEDICINE, VOL. 11, 141-158 (1992) META-ANALYSIS FOR 2 x 2 TABLES: A BAYESIAN APPROACH JOHN B. CARLIN Clinical Epidemiology and Biostatistics Unit, Royal Children s Hospital, Flemington Road,
More informationThe response to the Committee request for additional analyses in section 1.4, MSD follows:
MSD Hertford Road Hoddesdon, Hertfordshire EN11 9BU, UK Telephone +44 (0)1992 452644 Facsimile +44 (0)1992 468175 1 Kate Moore Technology Appraisals Project Manager National Institute for Health and Clinical
More informationToday: Binomial response variable with an explanatory variable on an ordinal (rank) scale.
Model Based Statistics in Biology. Part V. The Generalized Linear Model. Single Explanatory Variable on an Ordinal Scale ReCap. Part I (Chapters 1,2,3,4), Part II (Ch 5, 6, 7) ReCap Part III (Ch 9, 10,
More informationSimulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons
Song et al. BMC Medical Research Methodology 2012, 12:138 RESEARCH ARTICLE Open Access Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons Fujian Song
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationST440/550: Applied Bayesian Statistics. (10) Frequentist Properties of Bayesian Methods
(10) Frequentist Properties of Bayesian Methods Calibrated Bayes So far we have discussed Bayesian methods as being separate from the frequentist approach However, in many cases methods with frequentist
More informationBayesian Adjustments for Misclassified Data. Lawrence Joseph
Bayesian Adjustments for Misclassified Data Lawrence Joseph Bayesian Adjustments for Misclassified Data Lawrence Joseph Marcel Behr, Patrick Bélisle, Sasha Bernatsky, Nandini Dendukuri, Theresa Gyorkos,
More informationCritical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment
Review For reprint orders, please contact reprints@future-drugs.com Critical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment Marco Barbieri, Michael
More informationUsing Indirect Comparisons to Support a Health Technology Assessment (HTA)
Using Indirect Comparisons to Support a Health Technology Assessment (HTA) Chrissie Fletcher Executive Director & Regional Head Global Biostatistical Science, Amgen Disclaimer The views expressed herein
More informationHow Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health-Care Evaluation?
VALUE IN HEALTH 14 (2011) 371 380 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval How Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health-Care
More informationTreatment effect estimates adjusted for small-study effects via a limit meta-analysis
Treatment effect estimates adjusted for small-study effects via a limit meta-analysis Gerta Rücker 1, James Carpenter 12, Guido Schwarzer 1 1 Institute of Medical Biometry and Medical Informatics, University
More informationCost-effectiveness of apremilast (Otezla )
Cost-effectiveness of apremilast (Otezla ) alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs) for the treatment of active psoriatic arthritis in adult patients who have had an
More information